Rehabilitation and palliation of ovarian cancer patients

Part of the Collection de L’Académie Européenne de Médecine de Réadaptation book series (LACADEMIE)


The chief aim of all medical, potentially curative follow-up care measures (recurrence prevention, early detection and therapy of disease recurrence) is to lengthen survival time (fig. 1.1). The cancer disease thus represents the focus of curative follow-up care.


Ovarian Cancer Bowel Obstruction Ovarian Carcinoma Ovarian Cancer Patient Short Bowel Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. — Antoniou, Pharoah AP, Narodet S et al. (2003) Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies.. Am J Hum Genet 72: 1117–30PubMedCrossRefGoogle Scholar
  2. — Aspinal F, Hughes R, Higginson I et al. (2002) A user’s guide to the palliative care outcome scale. Palliative care & policy publications. Kings College, LondonGoogle Scholar
  3. — Barat M, Franchignoni F (2004) Assessment in physical medicine and rehabilitation. Maugeri Foundation books PI-ME Press PaviaGoogle Scholar
  4. — Bausewein C, Fegg M, Radbruch L et al. (2005) Validation and clinical application of the German version of the palliative care outcome. J Pain Symptom Manage 30: 51–62PubMedCrossRefGoogle Scholar
  5. — Bingham S, Riboli E (2004) Diet and Cancer. The European Prospective Investigation in Cancer and Nutrition. Nat Rev Cancer 4(3): 206–15PubMedCrossRefGoogle Scholar
  6. — Becker G, Galandi D, Blum HE (2006) Malignant ascites: Systematic review and guideline for treatment. Eur J Cancer 42: 589–97PubMedCrossRefGoogle Scholar
  7. — Bundesarbeitsgemeinschaft für Rehabilitation (2003) Rahmenempfehlungen zur ambulanten onkologischen Rehabilitation. Schriftenreihe der Bundesarbeitsgemeinschaft für Rehabilitation (BAR), FrankfurtGoogle Scholar
  8. — Carmack Taylor C (2004) Predictors of sexual functioning in ovarian cancer patients, J Clin Oncol 22: 881–9PubMedCrossRefGoogle Scholar
  9. — Chanan-Khan A, Srinivasan S, Czucman M (2004) Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2: 251–66PubMedGoogle Scholar
  10. — Classe JM, Catala L, Marchal F et al. (2004) Locoregional recurrence of ovarian cancer: The place of surgery. Bull Cancer 91,11: 827–32PubMedGoogle Scholar
  11. — Covey A (2005) Management of malignant pleural effusions and ascites. J Support Oncol 3: 169–76PubMedGoogle Scholar
  12. — Dunton JC (2002) Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7: 11–9PubMedCrossRefGoogle Scholar
  13. — Doyle C, Crump M, Pintilie M et al. (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancerGoogle Scholar
  14. — Dubois A, Schlaich M et al. (1999) Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Support Care cancer 7: 354CrossRefGoogle Scholar
  15. — Faries MB, Romeau JL (1999) Use of gastrostomy-and combined gastrojejunostomy tubes for enteral feeding. World J Surg 23: 603–7PubMedCrossRefGoogle Scholar
  16. — Gore M (2001) Relapses epithelial ovarian cancer. ASCO educational book 37th annual meeting, 2001, 468–76Google Scholar
  17. — Grueningen van V, Daly B (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 97: 638–44CrossRefGoogle Scholar
  18. — IARC (2003) Handbook of cancer prevention, No 8: Fruits and vegetables. International Agency for Research on Cancer (IARC-WHO)Google Scholar
  19. — Jatoi A, Windschitl H, Loprinzi C et al. (2002) Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia. J Clin Oncol, 20,2: 567–73PubMedCrossRefGoogle Scholar
  20. — Jatoi A, Podratz KC et al. (2004) Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J Support Oncol 2: 323–37PubMedGoogle Scholar
  21. — Junker A, Kretschmar A, Bohm U et al. (2004) Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis. Med. Monatsschr Pharm 27,10: 349–52PubMedGoogle Scholar
  22. — Kuschel B, Lux M, Goecke T et al. (2000) Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. European Journal of Cancer Prevention 9,3: 139–50PubMedCrossRefGoogle Scholar
  23. — Langseth H, Kjaerheim K (2004) Ovarian cancer and occupational exposure among pulp and paper employees in Norway. Scand J Work Environ Health 30,5: 356–61PubMedGoogle Scholar
  24. — Ledermann JA, Wheeler S (2004) How should we manage patients with “platinum sensitive” recurrent ovarian cancer? Cancer Invest 22,2: 2–10PubMedCrossRefGoogle Scholar
  25. — Levy MH, Cohen SD (2005) Sedation for the relief of refractory symptoms in the imminently dying: A fine intentional line. Semin Oncol 32: 237–46PubMedCrossRefGoogle Scholar
  26. — Lim JF, Ho YH (2001) Total colectomy with ileorectal anastomosis leads to appreciable loss in quality of life. Techniques in coloproctology 5,2: 79–83PubMedCrossRefGoogle Scholar
  27. — Mielke S, Sparreboom A, Mross K (2006) Peripheral neuropathy: A persisting challenge in paclitaxel-based regimens. Eur J Cancer 42: 24–30PubMedCrossRefGoogle Scholar
  28. — Norton TR, Manne SL, Rubin S et al. (2004) Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 1,22, 5: 919–26CrossRefGoogle Scholar
  29. — Parsons SL, Lang M, Steele R (1996) Malignant ascites. Eur J Surg Oncol 22: 237–9PubMedCrossRefGoogle Scholar
  30. — Paice J (2003) Mechanisms and mamagement of neuropathic pain in cancer. J support Oncol 1,2: 107–14PubMedGoogle Scholar
  31. — Pothuri B, Guirguis A, Gerdes H et al. (2004) The use of colorectal stents for palliation of large bowel obstruction due to recurrent gynaecologic cancer. Gynecol Oncol 95(3): 513–7PubMedCrossRefGoogle Scholar
  32. — Pothuri B, Meyer L, Gerardi M et al. (2004) Reoperation for palliation of recurrent malignant bowel obstruction in ovarian carcinoma. Gynecol Oncol 95,1: 193–5PubMedCrossRefGoogle Scholar
  33. — Schover L (2005) Sexuality and fertility after cancer. The American society of HematologyGoogle Scholar
  34. — Sood AK, Lush R, Geisler JP et al. (2004) Sequential intraperitoneal topotecan and oral chemotherapy in recurrent platinum-resistant ovarian carcinoma. Clin Cancer Res 15,10:6080–5CrossRefGoogle Scholar
  35. — Stewart D, Cheung A, Dancey J et al. (2000) Information needs and decisional preferences among women with ovarian cancer. Gynecol Oncol 77,3: 357–61PubMedCrossRefGoogle Scholar
  36. — Sun C, Ramirez P, Bodurka D (2007) Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4,1: 18–29PubMedCrossRefGoogle Scholar
  37. — Vadaparampil ST, Wey JP, Kinney AY (2004) Psychosocial aspects of genetic counselling and testing. Semin Oncol Nurs 20,3: 186–95PubMedCrossRefGoogle Scholar
  38. — Wan GJ, Counte MA, Cella DF (1997) The influence of personal expectations on cancer patients’ reports of health related quality of life. Psycho-oncology 6: 1–11PubMedCrossRefGoogle Scholar
  39. — Watson M, Forster C, Eccles D et al. (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a genetic testing in a U.K. multi-centre clinical cohort.Google Scholar
  40. — Watson T, Mock V (2004) Exercise as an intervention for cancer related fatigue. Phys Ther 84: 736–43PubMedGoogle Scholar
  41. — World Health Organization (2001) International classification of functioning, disabilities and health. www. Scholar

Copyright information

© Springer-Verlag France, Paris 2007

Personalised recommendations